Biogen stock plunged 30% after unfavorable FDA decision

17:44 9 November 2020
Biogen (BIIB.US) shares fell 30% during today 'session after U.S. Food and Drug Administration advisory panel voted against approving company's experimental Alzheimer’s disease drug aducanumab last Friday. The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 8-1 against recommending approval of Biogen’s aducanumab. Two other members of the panel voted "undecided." On November 4th aducanumab received overall favorable initial review from the FDA which sparked a historic rally during which company's shares rose 44% to $355.63. However, on Friday the outside panel of experts questioned the drug's effectiveness, dimming prospects it will be approved by the agency. It turned out that the drug didn't perform particularly well in its late-stage clinical program. The advisory committee said the single successful test, along with an earlier-stage study, aren't sufficient to prove aducanumab's effectiveness. Biogen stock was halted on Friday during the meeting.
Biogen (BIIB.US) launched today's session with a massive bearish price gap. If current sentiment prevails, the nearest support at $216.00 could be at risk. On the other hand, should buyers manage to regain control, then nearest resistance lies at $244.45. Source: xStation5

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.

Back

Join over 1.6 Million investors from around the world